The P323L substitution in the SARS-CoV-2 polymerase (NSP12) confers a selective advantage during infection

Autor: Goldswain, H, Dong, X, Penrice-Randal, R, Alruwaili, M, Shawli, GT, Prince, T, Williamson, MK, Raghwani, J, Randle, N, Jones, B, Donovan-Banfield, I, Salguero, FJ, Tree, JA, Hall, Y, Hartley, C, Erdmann, M, Bazire, J, Jearanaiwitayakul, T, Semple, MG, Openshaw, PJM, Baillie, JK, Emmett, SR, Digard, P, Matthews, DA, Turtle, L, Darby, AC, Davidson, AD, Carroll, MW, Hiscox, JA, Carson, G, Dunning, J, Horby, PW, Klenerman, P, Mentzer, AJ, Merson, L, Sigfrid, L, Stuart, D, Angus, B

Background: The mutational landscape of SARS-CoV-2 varies at the dominant viral genome sequence and minor genomic variant population. During the COVID-19 pandemic, an early substitution in the genome was the D614G change in the spike protein, associa

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______1064::cd284419ba5bf69b5d40b9b400e872ee
https://doi.org/10.1186/s13059-023-02881-5

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Publisher Correction: Refinement of an ovine-based immunoglobulin therapy against SARS-CoV-2, with comparison of whole IgG versus F(ab') 2 fragments.

Autor: Findlay-Wilson S; UK Health Security Agency (UKHSA), Porton Down, Salisbury, Wiltshire, SP4 0JG, UK., Easterbrook L; UK Health Security Agency (UKHSA), Porton Down, Salisbury, Wiltshire, SP4 0JG, UK., Smith S; International Therapeutic, Proteins Ltd, Longford, TAS, 7301, Australia., Pope N; International Therapeutic Proteins Ltd, Goleigh Farm, Hampshire, Selborne, GU34 3SE, UK., Aldridge M; MicroPharm Ltd, Station Road, Newcastle Emlyn, SA38 9BY, UK., Humphries G; Native Antigen Company, Langford Locks, Kidlington, Oxford, OX5 1LH, UK., Schuhmann H; Native Antigen Company, Langford Locks, Kidlington, Oxford, OX5 1LH, UK., Ngabo D; UK Health Security Agency (UKHSA), Porton Down, Salisbury, Wiltshire, SP4 0JG, UK., Rayner E; UK Health Security Agency (UKHSA), Porton Down, Salisbury, Wiltshire, SP4 0JG, UK., Otter A; UK Health Security Agency (UKHSA), Porton Down, Salisbury, Wiltshire, SP4 0JG, UK., Coleman T; UK Health Security Agency (UKHSA), Porton Down, Salisbury, Wiltshire, SP4 0JG, UK., Hicks B; UK Health Security Agency (UKHSA), Porton Down, Salisbury, Wiltshire, SP4 0JG, UK., Halkerston R; UK Health Security Agency (UKHSA), Porton Down, Salisbury, Wiltshire, SP4 0JG, UK., Apostolakis K; UK Health Security Agency (UKHSA), Porton Down, Salisbury, Wiltshire, SP4 0JG, UK., Taylor S; UK Health Security Agency (UKHSA), Porton Down, Salisbury, Wiltshire, SP4 0JG, UK., Fotheringham S; UK Health Security Agency (UKHSA), Porton Down, Salisbury, Wiltshire, SP4 0JG, UK., Horton A; UK Health Security Agency (UKHSA), Porton Down, Salisbury, Wiltshire, SP4 0JG, UK., CanoCejas I; UK Health Security Agency (UKHSA), Porton Down, Salisbury, Wiltshire, SP4 0JG, UK., Wand M; UK Health Security Agency (UKHSA), Porton Down, Salisbury, Wiltshire, SP4 0JG, UK., Tree JA; UK Health Security Agency (UKHSA), Porton Down, Salisbury, Wiltshire, SP4 0JG, UK., Sutton M; UK Health Security Agency (UKHSA), Porton Down, Salisbury, Wiltshire, SP4 0JG, UK., Graham V; UK Health Security Agency (UKHSA), Porton Down, Salisbury, Wiltshire, SP4 0JG, UK., Hewson R; UK Health Security Agency (UKHSA), Porton Down, Salisbury, Wiltshire, SP4 0JG, UK., Dowall S; UK Health Security Agency (UKHSA), Porton Down, Salisbury, Wiltshire, SP4 0JG, UK. stuart.dowall@ukhsa.gov.uk.

Publikováno v: Scientific reports [Sci Rep] 2023 Sep 18; Vol. 13 (1), pp. 15419. Date of Electronic Publication: 2023 Sep 18.